SML2522
Diprovocim-1
≥98% (HPLC)
别名:
(3S,3′S,4S,4′S)-1,1′-（1,4-苯二羰基）双[N-[(1S,2R)-2-苯基环丙基]-3,4-吡咯烷二甲酰胺, 3,4-吡咯烷二甲酰胺，1,1′-（1,4-苯二羰基）双[N-[(1S,2R)-2-苯基环丙基]-，（3S,3′S,4S,4′S）-
InChI key
ABZBNXFGYUSVCJ-UYMKNZQYSA-N
SMILES string
N7(C[C@H]([C@@H](C7)C(=O)N[C@@H]%10[C@H](C%10)c%11ccccc%11)C(=O)N[C@@H]8[C@H](C8)c9ccccc9)C(=O)c1ccc(cc1)C(=O)N2C[C@H]([C@@H](C2)C(=O)N[C@@H]5[C@H](C5)c6ccccc6)C(=O)N[C@@H]3[C@H](C3)c4ccccc4
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
相关类别
Biochem/physiol Actions
Diprovocim-1是Toll样受体TLR2和TLR1的强效激动剂，EC50值为100 pM。已显示Diprovocim-1与抗PD-L1治疗协同作用，抑制肿瘤生长，产生长期的抗肿瘤记忆，并治愈或延长了植入鼠黑素瘤B16-OVA的小鼠的存活期。
Toll样受体TLR2和TLR1激动剂
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Ying Wang et al.
Proceedings of the National Academy of Sciences of the United States of America, 115(37), E8698-E8706 (2018-08-29)
Successful cancer immunotherapy entails activation of innate immune receptors to promote dendritic cell (DC) maturation, antigen presentation, up-regulation of costimulatory molecules, and cytokine secretion, leading to activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs). Here we screened a synthetic library
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持